Tenaya Therapeutics prices $60 million public offering amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2025
0mins
Should l Buy TNYA?
Source: Globenewswire
Tenaya Therapeutics Inc's stock fell by 35.29% today, crossing below the 5-day SMA, as the broader market faced declines with the Nasdaq-100 down 1.62% and the S&P 500 down 0.92%.
The decline in Tenaya's stock is attributed to its announcement of a $60 million public offering of 50 million units at $1.20 each, aimed at funding the development of its gene therapies TN-201 and TN-401. This offering reflects strong market interest, but the stock's performance is also impacted by the overall market weakness, suggesting sector rotation as investors reassess their positions.
The public offering is expected to close around December 15, 2025, and if successful, will provide essential funding to advance Tenaya's R&D projects. However, the stock's significant drop indicates investor caution amid the current market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNYA
Wall Street analysts forecast TNYA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.665
Low
2.00
Averages
9.14
High
40.00
Current: 0.665
Low
2.00
Averages
9.14
High
40.00
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenaya Therapeutics Reports Q4 Results and Financing Update
- Earnings Report: Tenaya Therapeutics reported a Q4 GAAP EPS of -$0.12, aligning with market expectations, indicating financial stability amid ongoing operations.
- Cash Reserves Growth: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $100.5 million, a significant increase from $61.4 million in 2024, enhancing financial flexibility for future initiatives.
- Financing Update: The public offering in December 2025 raised net proceeds of $55.8 million after underwriting discounts and expenses, expected to sufficiently fund operations into the second half of 2027, supporting strategic growth plans.
- Collaboration Prospects: Tenaya anticipates an upfront payment from its collaboration with Alnylam, which will further bolster its financial position and support ongoing research and operational activities.
See More
Tenaya's TN-301 Outperforms Givinostat in DMD Cardiomyopathy
- Promising Preclinical Data: At the 2026 Muscular Dystrophy Association conference, Tenaya presented preclinical data showing that TN-301 significantly outperformed the approved pan-HDAC inhibitor Givinostat in improving muscle function and addressing DMD cardiomyopathy, highlighting its potential in treating cardiac, metabolic, and muscular diseases.
- Multi-Modal Mechanism: TN-301 operates through multiple mechanisms, including reducing inflammation and improving mitochondrial function, effectively correcting DMD-associated cardiomyocyte defects, and restoring muscle strength to wild-type levels in mouse models at a low dose of 3 mg/kg, showcasing its superior therapeutic effects.
- Good Safety Profile: In a Phase 1 clinical trial involving healthy adults, TN-301 demonstrated good tolerability across a wide dose range without serious adverse events or dose-limiting toxicities, indicating its safety and efficacy for clinical applications.
- Future Development Plans: Tenaya plans to advance TN-301 into Phase 2 clinical development targeting heart failure and DMD, aiming to address significant unmet needs in current treatments and drive the company's strategic growth in the biopharmaceutical sector.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tenaya and Alnylam Forge Collaboration for Genetic Heart Disease Targets
- Collaboration Overview: Tenaya Therapeutics has entered into a research collaboration agreement with Alnylam Pharmaceuticals to identify and validate up to 15 gene targets for cardiovascular diseases, showcasing a powerful alliance in the field of gene therapy.
- Financial Support: Tenaya will receive up to $10 million in upfront payments, along with reimbursement for related costs during the two-year validation period, and could earn up to $1.13 billion in milestone payments if all targets lead to successful therapeutics, significantly enhancing its liquidity.
- Technological Edge: Leveraging human induced pluripotent stem cell-derived cardiomyocytes and high-throughput screening technologies, Tenaya has generated over 150 genetic targets, which will accelerate the development of new therapies and enhance its competitive position in cardiovascular disease treatment.
- Strategic Implications: This collaboration not only demonstrates Tenaya's innovative capabilities in heart disease treatment but also has the potential to meet the growing market demand through the development of transformational therapies, further solidifying its leadership in the biotechnology sector.
See More
Tenaya Shares Drop Following $60 Million Equity Raise
Stock Performance: Tenaya Therapeutics (TNYA) stock is experiencing a significant decline, trading down 37.44% at 85 cents, with a session volume of 42.39 million compared to the average of 3.51 million.
Public Offering Announcement: The company has priced an underwritten public offering of 50 million units at $1.20 each, aiming to raise $60 million to support the development of its clinical candidates, particularly TN-201 and TN-401.
Clinical Trial Updates: Interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy shows it was well tolerated, with improvements in arrhythmia burden and no serious adverse events reported.
FDA Notification: Tenaya Therapeutics has received notification from the FDA that the clinical hold on the MyPEAK-1 Phase 1b/2a trial of TN-201 has been lifted, allowing further development of the treatment for hypertrophic cardiomyopathy.
See More
Tenaya Therapeutics Reports Q4 Results and Financing Update
- Earnings Report: Tenaya Therapeutics reported a Q4 GAAP EPS of -$0.12, aligning with market expectations, indicating financial stability amid ongoing operations.
- Cash Reserves Growth: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $100.5 million, a significant increase from $61.4 million in 2024, enhancing financial flexibility for future initiatives.
- Financing Update: The public offering in December 2025 raised net proceeds of $55.8 million after underwriting discounts and expenses, expected to sufficiently fund operations into the second half of 2027, supporting strategic growth plans.
- Collaboration Prospects: Tenaya anticipates an upfront payment from its collaboration with Alnylam, which will further bolster its financial position and support ongoing research and operational activities.
See More
Tenaya's TN-301 Outperforms Givinostat in DMD Cardiomyopathy
- Promising Preclinical Data: At the 2026 Muscular Dystrophy Association conference, Tenaya presented preclinical data showing that TN-301 significantly outperformed the approved pan-HDAC inhibitor Givinostat in improving muscle function and addressing DMD cardiomyopathy, highlighting its potential in treating cardiac, metabolic, and muscular diseases.
- Multi-Modal Mechanism: TN-301 operates through multiple mechanisms, including reducing inflammation and improving mitochondrial function, effectively correcting DMD-associated cardiomyocyte defects, and restoring muscle strength to wild-type levels in mouse models at a low dose of 3 mg/kg, showcasing its superior therapeutic effects.
- Good Safety Profile: In a Phase 1 clinical trial involving healthy adults, TN-301 demonstrated good tolerability across a wide dose range without serious adverse events or dose-limiting toxicities, indicating its safety and efficacy for clinical applications.
- Future Development Plans: Tenaya plans to advance TN-301 into Phase 2 clinical development targeting heart failure and DMD, aiming to address significant unmet needs in current treatments and drive the company's strategic growth in the biopharmaceutical sector.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tenaya and Alnylam Forge Collaboration for Genetic Heart Disease Targets
- Collaboration Overview: Tenaya Therapeutics has entered into a research collaboration agreement with Alnylam Pharmaceuticals to identify and validate up to 15 gene targets for cardiovascular diseases, showcasing a powerful alliance in the field of gene therapy.
- Financial Support: Tenaya will receive up to $10 million in upfront payments, along with reimbursement for related costs during the two-year validation period, and could earn up to $1.13 billion in milestone payments if all targets lead to successful therapeutics, significantly enhancing its liquidity.
- Technological Edge: Leveraging human induced pluripotent stem cell-derived cardiomyocytes and high-throughput screening technologies, Tenaya has generated over 150 genetic targets, which will accelerate the development of new therapies and enhance its competitive position in cardiovascular disease treatment.
- Strategic Implications: This collaboration not only demonstrates Tenaya's innovative capabilities in heart disease treatment but also has the potential to meet the growing market demand through the development of transformational therapies, further solidifying its leadership in the biotechnology sector.
See More
Tenaya Shares Drop Following $60 Million Equity Raise
Stock Performance: Tenaya Therapeutics (TNYA) stock is experiencing a significant decline, trading down 37.44% at 85 cents, with a session volume of 42.39 million compared to the average of 3.51 million.
Public Offering Announcement: The company has priced an underwritten public offering of 50 million units at $1.20 each, aiming to raise $60 million to support the development of its clinical candidates, particularly TN-201 and TN-401.
Clinical Trial Updates: Interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy shows it was well tolerated, with improvements in arrhythmia burden and no serious adverse events reported.
FDA Notification: Tenaya Therapeutics has received notification from the FDA that the clinical hold on the MyPEAK-1 Phase 1b/2a trial of TN-201 has been lifted, allowing further development of the treatment for hypertrophic cardiomyopathy.
See More
